Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential

Frontiers in Bioscience

Volumn 12, Issue 13, 2007, Pages 4839-4854

  Shankar, Sharmila ^a   Singh, Gyanendra ^a   Srivastava, Rakesh K ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Cancer; Chemoprevention; p53; Resveratrol; ROS; TRAIL

Indexed keywords

ARACHIS HYPOGAEA; MORUS (ANGIOSPERM); MORUS(ANGIOSPERM); VITACEAE;

RESVERATROL; STILBENE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELL CYCLE; CHEMISTRY; CHEMOPROPHYLAXIS; DIABETES MELLITUS; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; CELL CYCLE; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STILBENES;

EID: 34547684362     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2432     Document Type: Review

References (195)

1. Boyle, P., P. Maisonneuve & P. Napalkov: Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology, 46, 47-55 (1995)
2. Hong, J. H., K. S. Ahn, E. Bae, S. S. Jeon & H. Y. Choi: The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis (2006)
3. Manson, M. M., P. B. Farmer, A. Gescher & W. P. Steward: Innovative agents in cancer prevention. Recent Results Cancer Res, 166, 257-75 (2005)
4. Jang, D. S., B. S. Kang, S. Y. Ryu, I. M. Chang, K. R. Min & Y. Kim: Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem Pharmacol, 57, 705-12 (1999) (Pubitemid 29080762)
5. Inoue, H., X. F. Jiang, T. Katayama, S. Osada, K. Umesono & S. Namura: Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett, 352, 203-6 (2003) (Pubitemid 38367603)
6. Cos, P., T. De Bruyne, S. Apers, D. Vanden Berghe, L. Pieters & A. J. Vlietinck: Phytoestrogens: recent developments. Planta Med, 69, 589-99 (2003) (Pubitemid 37041052)
7. Agarwal, R.: Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol, 60, 1051-9 (2000)
8. Mitchell, K. O. & W. S. El-Deiry: Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol- 13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ, 10, 223-30 (1999) (Pubitemid 29196658)
9. Hsieh, T. C. & J. M. Wu: Grape-derived chemopreventive agent resveratrol decreases prostatespecific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res, 20, 225-8 (2000) (Pubitemid 30189758)
10. Bhat, K. P. & J. M. Pezzuto: Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci, 957, 210-29 (2002) (Pubitemid 34721666)
11. Jang, M., L. Cai, G. O. Udeani, K. V. Slowing, C. F. Thomas, C. W. Beecher, H. H. Fong, N. R. Farnsworth, A. D. Kinghorn, R. G. Mehta, R. C. Moon & J. M. Pezzuto: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20 (1997) (Pubitemid 127696281)
12. Srivastava, R. K., S. J. Sollott, L. Khan, R. Hansford, E. G. Lakatta & D. L. Longo: Bcl-2 and Bcl-X (L) block thapsigargin-induced nitric oxide generation, c-Jun. NH (2) - terminal kinase activity, and apoptosis. Mol Cell Biol, 19, 5659-74 (1999) (Pubitemid 29339923)
13. Kroemer, G. & J. C. Reed: Mitochondrial control of cell death. Nat Med, 6, 513-9 (2000) (Pubitemid 30305900)
14. Korsmeyer, S. J.: BCL-2 gene family and the regulation of programmed cell death. Cancer Res, 59, 1693s-1700s (1999) (Pubitemid 29165240)
15. Cory, S., D. C. Huang & J. M. Adams: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 22, 8590-607 (2003) (Pubitemid 38028528)
16. Oltvai, Z. N., C. L. Milliman & S. J. Korsmeyer: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-19 (1993) (Pubitemid 23259742)
17. Adams, J. M. & S. Cory: The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322-6 (1998) (Pubitemid 28406819)
18. Kelekar, A. & C. B. Thompson: Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol, 8, 324-30 (1998) (Pubitemid 28362590)
19. Reed, J. C.: Bcl-2 family proteins. Oncogene, 17, 3225-36 (1998) (Pubitemid 29043975)
20. McDonnell, J. M., D. Fushman, C. L. Milliman, S. J. Korsmeyer & D. Cowburn: Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell, 96, 625-34 (1999) (Pubitemid 29122805)
21. Srivastava, R. K., Q. S. Mi, J. M. Hardwick & D. L. Longo: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A, 96, 3775-80 (1999) (Pubitemid 29168986)
22. Srivastava, R. K., C. Y. Sasaki, J. M. Hardwick & D. L. Longo: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med, 190, 253-65 (1999) (Pubitemid 29354918)
23. Hickman, J. A., C. S. Potten, A. J. Merritt & T. C. Fisher: Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci, 345, 319-25 (1994)
24. Levine, B., J. E. Goldman, H. H. Jiang, D. E. Griffin & J. M. Hardwick: Bc1-2 protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci U S A, 93, 4810-5 (1996) (Pubitemid 26162833)
25. Fulda, S. & K. M. Debatin: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer, 41, 786-98 (2005) (Pubitemid 40342561)
26. Shankar, S., I. Siddiqui & R. K. Srivastava: Resveratrol sensitizes TRAIL-resistant human prostate cancer cells by generating reactive oxygen species, targeting p53 to mitochondria, and regulating Bcl-2 family members, IAPs and death receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. Cancer Res, in press, (2007)
27. Shankar, S., I. Siddiqui & R. K. Srivastava: Molecular mechanisms of resveratrol (3, 4, 5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem, in press, (2007)
28. Aggarwal, B. B. & S. Shishodia: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71, 1397-421 (2006)
29. Bhardwaj, A., G. Sethi, S. Vadhan-Raj, C. Bueso-Ramos, Y. Takada, U. Gaur, A. S. Nair, S. Shishodia & B. B. Aggarwal: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-{kappa}B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109, 2293-302 (2007) (Pubitemid 46425866)
30. Benitez, D. A., E. Pozo-Guisado, A. Alvarez-Barrientos, P. M. Fernandez-Salguero & E. A. Castellon: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl, 28, 282-93 (2007) (Pubitemid 46423911)
31. Kotha, A., M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A. S. Zervos, B. Carter, J. Turkson & R. Jove: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther, 5, 621-9 (2006)
32. Liang, Y. C., S. H. Tsai, L. Chen, S. Y. Lin-Shiau & J. K. Lin: Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol, 65, 1053-60 (2003) (Pubitemid 36349745)
33. Ferrer, P., M. Asensi, R. Segarra, A. Ortega, M. Benlloch, E. Obrador, M. T. Varea, G. Asensio, L. Jorda & J. M. Estrela: Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia, 7, 37-47 (2005) (Pubitemid 40209469)
34. Maulik, N.: Reactive oxygen species drives myocardial angiogenesis? Antioxid Redox Signal, 8, 2161-8 (2006) (Pubitemid 46489639)
35. Zhang, W., Z. Fei, H. N. Zhen, J. N. Zhang & X. Zhang: Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells. J Neurooncol, 81, 231-40 (2007) (Pubitemid 46165325)
36. Bruder, J. L., T. Hsieh, K. M. Lerea, S. C. Olson & J. M. Wu: Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol, 2:1 (2001)
37. She, Q. B., A. M. Bode, W. Y. Ma, N. Y. Chen & Z. Dong: Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res, 61, 1604-10 (2001) (Pubitemid 34292594)
38. Lin, H. Y., A. Shih, F. B. Davis, H. Y. Tang, L. J. Martino, J. A. Bennett & P. J. Davis: Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol, 168, 748-55 (2002) (Pubitemid 34793357)
39. Huang, C., W. Y. Ma, A. Goranson & Z. Dong: Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, 20, 237-42 (1999) (Pubitemid 29057555)
40. Kannan, K. & S. K. Jain: Oxidative stress and apoptosis. Pathophysiology, 7, 153-163 (2000)
41. Kroemer, G., N. Zamzami & S. A. Susin: Mitochondrial control of apoptosis. Immunol Today, 18, 44-51 (1997) (Pubitemid 27072433)
42. Macip, S., M. Igarashi, P. Berggren, J. Yu, S. W. Lee & S. A. Aaronson: Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol, 23, 8576-85 (2003) (Pubitemid 37433363)
43. Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler & B. Vogelstein: A model for p53-induced apoptosis. Nature, 389, 300-5 (1997) (Pubitemid 27406646)
44. Chandel, N. S., M. G. Vander Heiden, C. B. Thompson & P. T. Schumacker: Redox regulation of p53 during hypoxia. Oncogene, 19, 3840-8 (2000) (Pubitemid 30658974)
45. Bode, A. M. & Z. Dong: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer, 4, 793-805 (2004) (Pubitemid 39331151)
46. Notas, G., A. P. Nifli, M. Kampa, J. Vercauteren, E. Kouroumalis & E. Castanas: Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta, 1760, 1657-66 (2006) (Pubitemid 44667277)
47. Chander, V. & K. Chopra: Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Ren Fail, 28, 161-9 (2006)
48. Holian, O., S. Wahid, M. J. Atten & B. M. Attar: Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am J Physiol Gastrointest Liver Physiol, 282, G809-16 (2002) (Pubitemid 34651626)
49. Kim, A. L., Y. Zhu, H. Zhu, L. Han, L. Kopelovich, D. R. Bickers & M. Athar: Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol, 15, 538-46 (2006) (Pubitemid 43834489)
50. Nam, N. H.: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem, 6, 945-51 (2006)
51. Das, S., V. K. Alagappan, D. Bagchi, H. S. Sharma, N. Maulik & D. K. Das: Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol, 42, 281-9 (2005) (Pubitemid 40726331)
52. Madar, Z., N. Maayan, O. Sarit & A. Eliraz: Antioxidants modulate the nitric oxide system and SOD activity and expression in rat epithelial lung cells. Asia Pac J Clin Nutr, 13:S101 (2004)
53. Maehama, T. & J. E. Dixon: PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol, 9, 125-8 (1999) (Pubitemid 29161437)
54. Cairns, P., K. Okami, S. Halachmi, N. Halachmi, M. Esteller, J. G. Herman, J. Jen, W. B. Isaacs, G. S. Bova & D. Sidransky: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, 57, 4997-5000 (1997) (Pubitemid 27498107)
55. Guldberg, P., P. thor Straten, A. Birck, V. Ahrenkiel, A. F. Kirkin & J. Zeuthen: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res, 57, 3660-3 (1997) (Pubitemid 27381203)
56. Kohno, T., M. Takahashi, R. Manda & J. Yokota: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer, 22, 152-6 (1998) (Pubitemid 28208808)
57. Liu, W., C. D. James, L. Frederick, B. E. Alderete & R. B. Jenkins: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res, 57, 5254-7 (1997) (Pubitemid 27516358)
58. Di Cristofano, A. & P. P. Pandolfi: The multiple roles of PTEN in tumor suppression. Cell, 100, 387-90 (2000)
59. Dahia, P. L., R. C. Aguiar, J. Alberta, J. B. Kum, S. Caron, H. Sill, D. J. Marsh, J. Ritz, A. Freedman, C. Stiles & C. Eng: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet, 8, 185-93 (1999) (Pubitemid 29054260)
60. Wu, G. S., P. Saftig, C. Peters & W. S. El-Deiry: Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene, 16, 2177-83 (1998) (Pubitemid 28220647)
61. Datta, S. R., A. Brunet & M. E. Greenberg: Cellular survival: a play in three Akts. Genes Dev, 13, 2905-27 (1999)
62. Bellacosa, A., D. de Feo, A. K. Godwin, D. W. Bell, J. Q. Cheng, D. A. Altomare, M. Wan, L. Dubeau, G. Scambia, V. Masciullo & et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer, 64, 280-5 (1995)
63. Coffer, P. J. & J. R. Woodgett: Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem, 205:1217 (1992)
64. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh & M. E. Greenberg: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-41 (1997) (Pubitemid 27456390)
65. del Peso, L., M. Gonzalez-Garcia, C. Page, R. Herrera & G. Nunez: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278, 687-9 (1997) (Pubitemid 27464966)
66. Cardone, M. H., N. Roy, H. R. Stennicke, G. S. Salvesen, T. F. Franke, E. Stanbridge, S. Frisch & J. C. Reed: Regulation of cell death protease caspase-9 by phosphorylation. Science, 282, 1318-21 (1998) (Pubitemid 28524494)
67. Kang, J. J., M. D. Schaber, S. M. Srinivasula, E. S. Alnemri, G. Litwack, D. J. Hall & M. A. Bjornsti: Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J Biol Chem, 274, 3189-98 (1999) (Pubitemid 29075408)
68. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis & M. E. Greenberg: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96, 857-68 (1999) (Pubitemid 29165088)
69. Kops, G. J. & B. M. Burgering: Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med, 77, 656-65 (1999) (Pubitemid 29500958)
70. Romashkova, J. A. & S. S. Makarov: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401, 86-90 (1999)
71. Ozes, O. N., L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer & D. B. Donner: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401, 82-5 (1999)
72. Datta, S. R., A. Katsov, L. Hu, A. Petros, S. W. Fesik, M. B. Yaffe & M. E. Greenberg: 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell, 6, 41-51 (2000)
73. Datta, S. R., A. M. Ranger, M. Z. Lin, J. F. Sturgill, Y. C. Ma, C. W. Cowan, P. Dikkes, S. J. Korsmeyer & M. E. Greenberg: Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell, 3, 631-43 (2002) (Pubitemid 35339482)
74. Hill, B. & N. Kyprianou: Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). Oncol Rep, 9, 1151-6 (2002)
75. Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. A. Segal, D. R. Kaplan & M. E. Greenberg: Regulation of neuronal survival by the serinethreonine protein kinase Akt. Science, 275, 661-5 (1997) (Pubitemid 27061332)
76. Kaufmann, S. H. & M. O. Hengartner: Programmed cell death: alive and well in the new millennium. Trends Cell Biol, 11, 526-34 (2001) (Pubitemid 33079147)
77. Kennedy, S. G., A. J. Wagner, S. D. Conzen, J. Jordan, A. Bellacosa, P. N. Tsichlis & N. Hay: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev, 11, 701-13 (1997) (Pubitemid 27157159)
78. Khwaja, A.: Akt is more than just a Bad kinase. Nature, 401, 33-4 (1999)
79. Kulik, G. & M. J. Weber: Akt-dependent and - independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol, 18, 6711-8 (1998) (Pubitemid 28500558)
80. Chen, R. H., Y. H. Su, R. L. Chuang & T. Y. Chang: Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Aktdependent pathway. Oncogene, 17, 1959-68 (1998) (Pubitemid 28488464)
81. Kandasamy, K. & R. K. Srivastava: Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis in non-small cell lung cancer cells. Cancer Res, 62, 4929-37 (2002) (Pubitemid 34984416)
82. Hill, M. M. & B. A. Hemmings: Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther, 93, 243-51 (2002) (Pubitemid 34615565)
83. Graff, J. R., B. W. Konicek, A. M. McNulty, Z. Wang, K. Houck, S. Allen, J. D. Paul, A. Hbaiu, R. G. Goode, G. E. Sandusky, R. L. Vessella & B. L. Neubauer: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem, 275, 24500-5 (2000) (Pubitemid 30626543)
84. Chen, Q., B. Gong, A. S. Mahmoud-Ahmed, A. Zhou, E. D. Hsi, M. Hussein & A. Almasan: Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood, 98, 2183-92 (2001)
85. Ghosh, S., M. J. May & E. B. Kopp: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 16, 225-60 (1998) (Pubitemid 28183365)
86. Baldwin, A. S., Jr.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 14, 649-83 (1996) (Pubitemid 26130197)
87. Karin, M. & Y. Ben-Neriah: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol, 18, 621-63 (2000) (Pubitemid 30365393)
88. Mayo, M. W. & A. S. Baldwin: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta, 1470, M55-62 (2000) (Pubitemid 30155606)
89. Gilmore, T. D., M. Koedood, K. A. Piffat & D. W. White: Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene, 13, 1367-78 (1996)
90. Luque, I. & C. Gelinas: Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol, 8, 103-11 (1997)
91. Pahl, H. L.: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-66 (1999)
92. Kim, D. W., M. A. Sovak, G. Zanieski, G. Nonet, R. Romieu-Mourez, A. W. Lau, L. J. Hafer, P. Yaswen, M. Stampfer, A. E. Rogers, J. Russo & G. E. Sonenshein: Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis, 21, 871-9 (2000) (Pubitemid 30265128)
93. Pestell, R. G., C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee & A. Arnold: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev, 20, 501-34 (1999) (Pubitemid 30647078)
94. Joyce, D., C. Albanese, J. Steer, M. Fu, B. Bouzahzah & R. G. Pestell: NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev, 12, 73-90 (2001) (Pubitemid 32294588)
95. Gillett, C., V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes & G. Peters: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res, 54, 1812-7 (1994) (Pubitemid 24116192)
96. McIntosh, G. G., J. J. Anderson, I. Milton, M. Steward, A. H. Parr, M. D. Thomas, J. A. Henry, B. Angus, T. W. Lennard & C. H. Horne: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11, 885-91 (1995)
97. Wang, L., T. Habuchi, K. Mitsumori, Z. Li, T. Kamoto, H. Kinoshita, N. Tsuchiya, K. Sato, C. Ohyama, A. Nakamura, O. Ogawa & T. Kato: Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20 (2003) (Pubitemid 35424214)
98. Reissmann, P. T., H. Koga, R. A. Figlin, E. C. Holmes & D. J. Slamon: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-smallcell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol, 125, 61-70 (1999) (Pubitemid 29161456)
99. Le Marchand, L., A. Seifried, A. Lum-Jones, T. Donlon & L. R. Wilkens: Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. Jama, 290, 2843-8 (2003) (Pubitemid 37509493)
100. Bringuier, P. P., Y. Tamimi, E. Schuuring & J. Schalken: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene, 12, 1747-53 (1996) (Pubitemid 26146299)
101. Wang, L., T. Habuchi, T. Takahashi, K. Mitsumori, T. Kamoto, Y. Kakehi, H. Kakinuma, K. Sato, A. Nakamura, O. Ogawa & T. Kato: Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis, 23, 257-64 (2002) (Pubitemid 34224000)
102. Hung, W. C., C. Y. Chai, J. S. Huang & L. Y. Chuang: Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol, 27, 1324-8 (1996)
103. Zhang, Y. J., W. Jiang, C. J. Chen, C. S. Lee, S. M. Kahn, R. M. Santella & I. B. Weinstein: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun, 196, 1010-6 (1993) (Pubitemid 23337708)
104. Gansauge, S., F. Gansauge, M. Ramadani, H. Stobbe, B. Rau, N. Harada & H. G. Beger: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res, 57, 1634-7 (1997) (Pubitemid 27199649)
105. Cavalla, P., A. Dutto, R. Piva, P. Richiardi, R. Grosso & D. Schiffer: Cyclin D1 expression in gliomas. Acta Neuropathol (Berl), 95, 131-5 (1998) (Pubitemid 28076006)
106. Sauter, E. R., U. C. Yeo, A. von Stemm, W. Zhu, S. Litwin, D. S. Tichansky, G. Pistritto, M. Nesbit, D. Pinkel, M. Herlyn & B. C. Bastian: Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res, 62, 3200-6 (2002) (Pubitemid 34602414)
107. Kim, H., E. K. Ham, Y. I. Kim, J. G. Chi, H. S. Lee, S. H. Park, Y. M. Jung, N. K. Myung, M. J. Lee & J. J. Jang: Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas. Cancer Lett, 131, 177-83 (1998) (Pubitemid 28479787)
108. Hemmer, S., V. M. Wasenius, C. Haglund, Y. Zhu, S. Knuutila, K. Franssila & H. Joensuu: Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol, 158, 1355-62 (2001) (Pubitemid 32281299)
109. Bergsagel, P. L. & W. M. Kuehl: Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev, 194, 96-104 (2003) (Pubitemid 36886431)
110. Liu, J. H., C. C. Yen, Y. C. Lin, J. P. Gau, M. H. Yang, T. C. Chao, L. T. Hsiao, W. S. Wang, Y. C. Tsai & P. M. Chen: Overexpression of cyclin D1 in acceleratedphase chronic myeloid leukemia. Leuk Lymphoma, 45, 2419-25 (2004)
111. Albanese, C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold & R. G. Pestell: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem, 270, 23589-97 (1995)
112. Matsumura, I., T. Kitamura, H. Wakao, H. Tanaka, K. Hashimoto, C. Albanese, J. Downward, R. G. Pestell & Y. Kanakura: Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokinedependent growth of hematopoietic cells. Embo J, 18, 1367-77 (1999) (Pubitemid 29110320)
113. Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell & A. Ben-Ze'ev: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A, 96, 5522-7 (1999) (Pubitemid 29234650)
114. Watanabe, G., C. Albanese, R. J. Lee, A. Reutens, G. Vairo, B. Henglein & R. G. Pestell: Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol, 18, 3212-22 (1998) (Pubitemid 28240494)
115. Watanabe, G., A. Howe, R. J. Lee, C. Albanese, I. W. Shu, A. N. Karnezis, L. Zon, J. Kyriakis, K. Rundell & R. G. Pestell: Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci U S A, 93, 12861-6 (1996) (Pubitemid 26382734)
116. Wang, T. C., R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold & E. V. Schmidt: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369, 669-71 (1994) (Pubitemid 24199473)
117. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh & D. H. Lynch: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63 (1999) (Pubitemid 29068521)
118. Srivastava, R. K.: Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun, 4, 67-75 (2000) (Pubitemid 32183166)
119. Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis & J. Tschopp: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol, 2, 241-3 (2000)
120. Suliman, A., A. Lam, R. Datta & R. K. Srivastava: Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene, 20, 2122-33 (2001) (Pubitemid 32424006)
121. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni & V. M. Dixit: The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-3 (1997) (Pubitemid 27161256)
122. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin & C. T. Rauch: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J, 16, 5386-97 (1997) (Pubitemid 27380146)
123. Degli-Esposti, M. A., P. J. Smolak, H. Walczak, J. Waugh, C. P. Huang, R. F. DuBose, R. G. Goodwin & C. A. Smith: Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med, 186, 1165-70 (1997) (Pubitemid 27441160)
124. Degli-Esposti, M. A., W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith & R. G. Goodwin: The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7, 813-20 (1997) (Pubitemid 28064894)
125. Golstein, P.: Cell death: TRAIL and its receptors. Curr Biol, 7, R750-3 (1997) (Pubitemid 28017053)
126. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski & A. Ashkenazi: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-21 (1997) (Pubitemid 27366733)
127. Marsters, S. A., J. P. Sheridan, R. M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A. D. Goddard, P. Godowski & A. Ashkenazi: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol, 7, 1003-6 (1997) (Pubitemid 28017080)
128. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch & M. Z. Kubin: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol, 161, 2833-40 (1998) (Pubitemid 28425704)
129. Ashkenazi, A. & V. M. Dixit: Death receptors: signaling and modulation. Science, 281, 1305-8 (1998) (Pubitemid 28406815)
130. Muzio, M.: Signalling by proteolysis: death receptors induce apoptosis. Int J Clin Lab Res, 28, 141-7 (1998)
131. Wang, C. Y., M. W. Mayo & A. S. Baldwin, Jr.: TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science, 274, 784-7 (1996) (Pubitemid 26398259)
132. Kandasamy, K., S. M. Srinivasula, E. S. Alnemri, C. B. Thompson, S. J. Korsmeyer, J. L. Bryant & R. K. Srivastava: Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res, 63, 1712-21 (2003) (Pubitemid 36373665)
133. Srinivasula, S. M., S. Gupta, P. Datta, Z. Zhang, R. Hegde, N. Cheong, T. Fernandes-Alnemri & E. S. Alnemri: Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem, 278, 31469-72 (2003) (Pubitemid 37048322)
134. Kroemer, G.: Mitochondrial control of apoptosis: an overview. Biochem Soc Symp, 66, 1-15 (1999) (Pubitemid 129639017)
135. Green, D. R.: Apoptotic pathways: the roads to ruin. Cell, 94, 695-8 (1998)
136. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh & R. H. Schwall: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, 155-62 (1999)
137. Keane, M. M., S. A. Ettenberg, M. M. Nau, E. K. Russell & S. Lipkowitz: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res, 59, 734-41 (1999) (Pubitemid 29076075)
138. Singh, A., P. S. Naidu & S. K. Kulkarni: Reversal of aging and chronic ethanol-induced cognitive dysfunction by quercetin a bioflavonoid. Free Radic Res, 37, 1245-52 (2003) (Pubitemid 37322203)
139. Shankar, S., T. R. Singh, X. Chen, H. Thakkar, J. Firnin & R. K. Srivastava: The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol, 24, 1133-40 (2004)
140. Chen, Q., S. Ray, M. A. Hussein, G. Srkalovic & A. Almasan: Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma, 44, 1209-14 (2003) (Pubitemid 36609115)
141. Kopp, P.: Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol, 138, 619-20 (1998) (Pubitemid 28313808)
142. Aumont, V., S. Krisa, E. Battaglia, P. Netter, T. Richard, J. M. Merillon, J. Magdalou & N. Sabolovic: Regioselective and stereospecific glucuronidation of trans-and cis-resveratrol in human. Arch Biochem Biophys, 393, 281-9 (2001) (Pubitemid 32907185)
143. Brill, S. S., A. M. Furimsky, M. N. Ho, M. J. Furniss, Y. Li, A. G. Green, W. W. Bradford, C. E. Green, I. M. Kapetanovic & L. V. Iyer: Glucuronidation of transresveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol, 58, 469-79 (2006)
144. De Santi, C., A. Pietrabissa, R. Spisni, F. Mosca & G. M. Pacifici: Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica, 30, 857-66 (2000)
145. De Santi, C., A. Pietrabissa, R. Spisni, F. Mosca & G. M. Pacifici: Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica, 30, 609-17 (2000) (Pubitemid 30449570)
146. Walle, T., F. Hsieh, M. H. DeLegge, J. E. Oatis, Jr. & U. K. Walle: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos, 32, 1377-82 (2004) (Pubitemid 39564557)
147. Wenzel, E., T. Soldo, H. Erbersdobler & V. Somoza: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res, 49, 482-94 (2005) (Pubitemid 40780395)
148. Wenzel, E. & V. Somoza: Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res, 49, 472-81 (2005) (Pubitemid 40780394)
149. Potter, G. A., L. H. Patterson, E. Wanogho, P. J. Perry, P. C. Butler, T. Ijaz, K. C. Ruparelia, J. H. Lamb, P. B. Farmer, L. A. Stanley & M. D. Burke: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer, 86, 774-8 (2002) (Pubitemid 34250822)
150. Piver, B., M. Fer, X. Vitrac, J. M. Merillon, Y. Dreano, F. Berthou & D. Lucas: Involvement of cytochrome P450 1A2 in the biotransformation of transresveratrol in human liver microsomes. Biochem Pharmacol, 68, 773-82 (2004) (Pubitemid 38953459)
151. Walle, T., U. K. Walle, D. Sedmera & M. Klausner: Benzo[A]pyrene-induced oral carcinogenesis and chemoprevention: studies in bioengineered human tissue. Drug Metab Dispos, 34, 346-50 (2006) (Pubitemid 43290890)
152. Gescher, A. J. & W. P. Steward: Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7 (2003) (Pubitemid 37310248)
153. Goldberg, D. M., J. Yan & G. J. Soleas: Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem, 36, 79-87 (2003) (Pubitemid 36126394)
154. Yu, C., Y. G. Shin, A. Chow, Y. Li, J. W. Kosmeder, Y. S. Lee, W. H. Hirschelman, J. M. Pezzuto, R. G. Mehta & R. B. van Breemen: Human, rat, and mouse metabolism of resveratrol. Pharm Res, 19, 1907-14 (2002) (Pubitemid 36016041)
155. Kuhnle, G., J. P. Spencer, G. Chowrimootoo, H. Schroeter, E. S. Debnam, S. K. Srai, C. Rice-Evans & U. Hahn: Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun, 272, 212-7 (2000) (Pubitemid 30444924)
156. Signorelli, P. & R. Ghidoni: Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem, 16, 449-66 (2005) (Pubitemid 41039220)
157. Miksits, M., A. Maier-Salamon, S. Aust, T. Thalhammer, G. Reznicek, O. Kunert, E. Haslinger, T. Szekeres & W. Jaeger: Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica, 35, 1101-19 (2005) (Pubitemid 43163249)
158. Busquets, S., E. Ametller, G. Fuster, M. Olivan, V. Raab, J. M. Argiles & F. J. Lopez-Soriano: Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett, 245, 144-8 (2007) (Pubitemid 44959346)
159. Kimura, Y. & H. Okuda: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr, 131, 1844-9 (2001) (Pubitemid 32520456)
160. Tseng, S. H., S. M. Lin, J. C. Chen, Y. H. Su, H. Y. Huang, C. K. Chen, P. Y. Lin & Y. Chen: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res, 10, 2190-202 (2004) (Pubitemid 38375581)
161. Brakenhielm, E., R. Cao & Y. Cao: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. Faseb J, 15, 1798-800 (2001)
162. Chanvitayapongs, S., B. Draczynska-Lusiak & A. Y. Sun: Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport, 8, 1499-502 (1997) (Pubitemid 27242563)
163. Belguendouz, L., L. Fremont & M. T. Gozzelino: Interaction of transresveratrol with plasma lipoproteins. Biochem Pharmacol, 55, 811-6 (1998) (Pubitemid 28319644)
164. Rotondo, S., G. Rajtar, S. Manarini, A. Celardo, D. Rotillo, G. de Gaetano, V. Evangelista & C. Cerletti: Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol, 123, 1691-9 (1998) (Pubitemid 28182053)
165. Frankel, E. N., A. L. Waterhouse & J. E. Kinsella: Inhibition of human LDL oxidation by resveratrol. Lancet, 341, 1103-4 (1993) (Pubitemid 23114451)
166. Li, H. F., S. A. Chen & S. N. Wu: Evidence for the stimulatory effect of resveratrol on Ca (2+)-activated K+ current in vascular endothelial cells. Cardiovasc Res, 45, 1035-45 (2000)
167. Orallo, F., E. Alvarez, M. Camina, J. M. Leiro, E. Gomez & P. Fernandez: The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol, 61, 294-302 (2002) (Pubitemid 34112803)
168. Bhat, K. P. L., J. W. Kosmeder, 2nd & J. M. Pezzuto: Biological effects of resveratrol. Antioxid Redox Signal, 3, 1041-64 (2001) (Pubitemid 34027361)
169. ElAttar, T. M. & A. S. Virji: Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs, 10, 187-93 (1999) (Pubitemid 29141305)
170. Heredia, A., C. Davis & R. Redfield: Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr, 25, 246-55 (2000) (Pubitemid 32010127)
171. Faith, S. A., T. J. Sweet, E. Bailey, T. Booth & J. J. Docherty: Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res, 72, 242-51 (2006) (Pubitemid 44708307)
172. Naesens, L., P. Bonnafous, H. Agut & E. De Clercq: Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol, 37 Suppl 1, S69-75 (2006)
173. Docherty, J. J., T. J. Sweet, E. Bailey, S. A. Faith & T. Booth: Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res, 72, 171-7 (2006) (Pubitemid 44708309)
174. Li, Y. Q., Z. L. Li, W. J. Zhao, R. X. Wen, Q. W. Meng & Y. Zeng: Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication. Eur J Med Chem, 41, 1084-9 (2006) (Pubitemid 44353865)
175. Subbaramaiah, K., W. J. Chung, P. Michaluart, N. Telang, T. Tanabe, H. Inoue, M. Jang, J. M. Pezzuto & A. J. Dannenberg: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem, 273, 21875-82 (1998) (Pubitemid 28405365)
176. Baeuerle, P. A. & V. R. Baichwal: NF-kappa B as a frequent target for immunosuppressive and antiinflammatory molecules. Adv Immunol, 65, 111-37 (1997) (Pubitemid 27323247)
177. Holmes-McNary, M. & A. S. Baldwin, Jr.: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res, 60, 3477-83 (2000) (Pubitemid 30482167)
178. Chi, T. C., W. P. Chen, T. L. Chi, T. F. Kuo, S. S. Lee, J. T. Cheng & M. J. Su: Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci (2007)
179. Ates, O., S. Cayli, E. Altinoz, I. Gurses, N. Yucel, M. Sener, A. Kocak & S. Yologlu: Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem, 294, 137-44 (2007) (Pubitemid 46188894)
180. Sharma, S., K. Chopra & S. K. Kulkarni: Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res, 21, 278-83 (2007) (Pubitemid 46479679)
181. Su, H. C., L. M. Hung & J. K. Chen: Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab, 290, E1339-46 (2006)
182. Sharma, S., M. Anjaneyulu, S. K. Kulkarni & K. Chopra: Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology, 76, 69-75 (2006) (Pubitemid 43131538)
183. Gentilli, M., J. X. Mazoit, H. Bouaziz, D. Fletcher, R. F. Casper, D. Benhamou & J. F. Savouret: Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci, 68, 1317-21 (2001) (Pubitemid 32168034)
184. Torres-Lopez, J. E., M. I. Ortiz, G. Castaneda-Hernandez, R. Alonso-Lopez, R. Asomoza-Espinosa & V. Granados-Soto: Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci, 70, 1669-76 (2002) (Pubitemid 34178374)
185. Granados-Soto, V., C. F. Arguelles & M. I. Ortiz: The peripheral antinociceptive effect of resveratrol is associated with activation of potassium channels. Neuropharmacology, 43, 917-23 (2002) (Pubitemid 35217730)
186. Valenzano, D. R. & A. Cellerino: Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle, 5, 1027-32 (2006) (Pubitemid 43778734)
187. Kubota, T., Y. Uemura, M. Kobayashi & H. Taguchi: Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res, 23, 4039-46 (2003) (Pubitemid 37474362)
188. Duraj, J., J. Bodo, M. Sulikova, P. Rauko & J. Sedlak: Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells. Neoplasma, 53, 384-92 (2006) (Pubitemid 44689851)
189. Rezk, Y. A., S. S. Balulad, R. S. Keller & J. A. Bennett: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol, 194, e23-6 (2006)
190. Fulda, S. & K. M. Debatin: Modulation of TRAIL signaling for cancer therapy. Vitam Horm, 67, 275-90 (2004) (Pubitemid 39753668)
191. Fuggetta, M. P., G. Lanzilli, M. Tricarico, A. Cottarelli, R. Falchetti, G. Ravagnan & E. Bonmassar: Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. J Exp Clin Cancer Res, 25, 189-93 (2006) (Pubitemid 44113862)
192. Scifo, C., A. Milasi, A. Guarnera, F. Sinatra & M. Renis: Resveratrol and propolis extract: an insight into the morphological and molecular changes induced in DU145 cells. Oncol Res, 15, 409-21 (2006)
193. Chen, M. L., J. Li, W. R. Xiao, L. Sun, H. Tang, L. Wang, L. Y. Wu, X. Chen & H. F. Xie: Protective effect of resveratrol against oxidative damage of UVA irradiated HaCaT cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 31, 635-9 (2006) (Pubitemid 44645932)
194. Gautam, S. C., Y. X. Xu, M. Dumaguin, N. Janakiraman & R. A. Chapman: Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant, 25, 639-45 (2000) (Pubitemid 30156589)
195. Scarlatti, F., G. Sala, C. Ricci, C. Maioli, F. Milani, M. Minella, M. Botturi & R. Ghidoni: Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett (2007)